Drug Profile
Research programme: anticancer and antiviral therapeutics - MultiCell Technologies
Alternative Names: Ig-NP; IgP therapeutic; MCT-475; MCT-485Latest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator MultiCell Technologies Inc
- Developer MultiCell Technologies Inc; University Health Network
- Class Immunoglobulin fusion proteins; Recombinant fusion proteins; RNA
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Immunomodulators; Immunostimulants; T lymphocyte stimulants; Toll-like receptor 3 agonists; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists; Toll-like receptor agonists; Tumour necrosis factor alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Liver cancer; Viral hepatitis
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for preclinical development in Viral-hepatitis in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Liver cancer in USA (Parenteral)